Trials / Completed
CompletedNCT00028288
Study of Daclizumab in Patients With Chronic, Persistent Asthma
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Daclizumab in Patients With Chronic, Persistent Asthma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (planned)
- Sponsor
- Facet Biotech · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate an investigational medication to treat chronic persistent asthma. The research is being conducted at up to 22 clinical research sites in the US and is open to both men and women ages 18 to 70 years old. Participants in the study will have a number of visits to a research site over a 10-month period. All study-related care and medication is provided to qualified participants at no cost: this includes all visits, examinations and laboratory work.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Daclizumab |
Timeline
- Start date
- 2001-09-01
- Primary completion
- 2003-12-01
- Completion
- 2003-12-01
- First posted
- 2001-12-20
- Last updated
- 2012-03-13
Locations
18 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00028288. Inclusion in this directory is not an endorsement.